Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00420160
Other study ID # 1R03CA119747
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received January 8, 2007
Last updated April 10, 2015
Start date February 2007
Est. completion date December 2008

Study information

Verified date April 2015
Source The Miriam Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study compares the effects of a standard smoking cessation treatment, including one-time brief counseling and provision of nicotine patch plus an 8-week moderate intensity exercise program versus the same standard smoking cessation treatment plus equivalent contact control among 60 healthy women. We hypothesize that participants in the smoking cessation plus moderate intensity exercise condition will be more likely to quit smoking than participants in the smoking cessation treament plus contact control condition.


Description:

This study compares the effects of a standard smoking cessation treatment, including one-time brief counseling and provision of nicotine patch plus an 8-week moderate intensity exercise program versus the same standard smoking cessation treatment plus equivalent contact control among 60 healthy women. A number of techniques will be used to increase compliance with the treatment program, thus more effectively isolating the effects of exercise. These include: (1) a two-week run-in period prior to randomization; (2) use of behavioral contracting prior to participant randomization; and (3) performance of all exercise on-site. Smoking cessation outcomes (continuous abstinence and point prevalence abstinence) will be verified by carbon monoxide and saliva cotinine. Physical activity will be evaluated by attendance at the supervised sessions. We hypothesize that participants in the smoking cessation plus moderate intensity exercise condition will be more likely to quit smoking than participants in the smoking cessation treament plus contact control condition.


Recruitment information / eligibility

Status Completed
Enrollment 59
Est. completion date December 2008
Est. primary completion date June 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Healthy sedentary smokers (> 4 per day for at least one year)

- Ages 18 to 65 years

- Must be able to give informed consent

- Must live in the area for the next 3 months

- Willing to use the nicotine patch to attempt smoking cessation

- Must receive consent to participate from primary care physician

Exclusion Criteria:

- Cannot read or write fluently in the English language

- Pregnancy or plans to attempt pregnancy

- 60 minutes or more per week of moderate or vigorous physical activity

- Smokes cigars, pipes, or uses smokeless tobacco at least once per week

- Currently in a quit smoking program

- Currently using NRT of any kind or using any other quit smoking method or treatment

- Never had an adverse reaction to the nicotine patch resulting in discontinuation of use

- Poor willingness or inability to comply with protocol requirements

- An employee of the Centers for Behavioral and Preventive Medicine

- Previous participant in Commit to Quit or Fit to Quit smoking cessation studies

- Another member of the household is or has been enrolled in this study

- Currently taking a medication that might impact heart rate response, including but not limited to:

Acebutolol Atenolol Carvedilol Metoprolol Nadolol Pindolol Propranolol Timolol

Medical problems:

- Cardiac disease of any kind such as angina, a history of myocardial infarction or valve disease including mitral valve prolapse. Anyone with an interventional procedure such as a stent

- Pain, discomfort (or other anginal equivalent) in the chest, neck, jaw, arms or other areas that may be due to ischemia

- Cerebrovasular disease such as stroke or history of transient ischemic attacks

- Peripheral vascular disease (such as claudication)

- Diabetes (both Type I and II)

- Chronic infectious disease (HIV, hepatitis) (hepatitis A is okay)

- Liver disease

- Cystic fibrosis (CF)

- Chronic obstructive pulmonary disease (COPD) (see asthma and bronchitis under questionable)

- Interstitial lung disease

- Emphysema

- Chronic Bronchitis

- Orthopnea (difficulty breathing except in the upright position) or paroxysmal nocturnal dyspnea (sudden shortness of breath at night typically triggered by lying down)

- Current diagnosis of Chronic Fatigue Syndrome

- Current diagnosis of Fibromyalgia

- Abnormal exercise stress test

- Hypertension (anyone currently being followed and/or treated for hypertension)

- Cancer treatment (other than skin cancer) within the past 6 months

- Musculoskeletal problems such as osteoarthritis, gout, osteoporosis or back, hip or knee pain that can interfere with physical activity (i.e., walking at a brisk pace - about 3-mph)

- Any other serious medical condition that might make exercise unsafe or unwise

Psychiatric Problems

- Hospitalization for a psychiatric disorder in the last 6 months

- Currently suicidal or psychotic, (or suicidal/psychotic in last 6 months)

- Self-report of more than three alcoholic drinks per day on 5 or more days; 5 or more alcoholic drinks on 3 or more days

- Taking these specific medications for psychiatric problems: Mood stabilizer (Lithium, Depakote, Neurontin), Antipsychotics (Haldol, Clozaril, Risperdal)

- Must be on other current psychiatric medications for at least three months

REQUIRES MD CONSENT FOR THE SPECIFIC CONDITION

- Lightheadedness, dizziness, vertigo, or fainting

- Last electrocardiogram (EKG) performed was abnormal

- Anemia

- Previous ETT for medical reason with normal results

- Irregular heart beats or palpitations in the past two years

- Heart murmurs in the past two years - the person will need physician's consent and an echocardiogram showing no evidence of significant heart disease

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Behavioral:
Smoking cessation treatment plus moderate intensity exercise

Smoking cessation treatment plus health education


Locations

Country Name City State
United States The Miriam Hospital Providence Rhode Island

Sponsors (2)

Lead Sponsor Collaborator
The Miriam Hospital National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Williams DM, Dunsiger S, Whiteley JA, Ussher MH, Ciccolo JT, Jennings EG. Acute effects of moderate intensity aerobic exercise on affective withdrawal symptoms and cravings among women smokers. Addict Behav. 2011 Aug;36(8):894-7. doi: 10.1016/j.addbeh.201 — View Citation

Williams DM, Whiteley JA, Dunsiger S, Jennings EG, Albrecht AE, Ussher MH, Ciccolo JT, Parisi AF, Marcus BH. Moderate intensity exercise as an adjunct to standard smoking cessation treatment for women: a pilot study. Psychol Addict Behav. 2010 Jun;24(2):3 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 7-day point prevalence smoking abstinence verified by saliva cotinine taken post-intervention (8 weeks after baseline) No
Secondary 7-day point prevalence smoking abstinence verified by saliva cotinine taken one month post-intervention (12 weeks after baseline) No
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk